1377 Preclinical characterization of D3L-001, a novel bispecific antibody that enhance phagocytosis and eradication of HER2 positive solid tumor via HER2 and CD47 dual blockade

Abstract

BackgroundHER2 is overexpressed in different solid tumors, including 15-20% of breast cancer. The advent of HER2-targeted drugs, including antibodies (Ab), TKI and ADC, have revolutionized HER2+ cancer treatment; however, the...